Inventiva, MoonLake Immunotherapeutics, and Other Major Stocks Decline in Monday's Pre-Market Trading
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 29 2025
0mins
Source: Benzinga
U.S. Stock Futures: U.S. stock futures rose this morning, with Dow futures increasing by over 100 points, indicating a positive market outlook.
Inventiva's Performance: Inventiva ADR shares fell 5.5% in pre-market trading after reporting a loss of $(1.84) per share, significantly worse than the expected loss of 41 cents, along with quarterly sales that missed estimates.
Other Stocks Declining: Several other stocks experienced significant declines in pre-market trading, including MoonLake Immunotherapeutics, which dropped 86.3%, and Cellectis SA, which fell 10.4%.
Market Reactions: Other notable declines included Quantum-Si Inc, Penguin Solutions Inc, and Lithium Americas Corp, reflecting a broader trend of negative performance among various stocks in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 49.640
Low
42.00
Averages
54.67
High
70.00
Current: 49.640
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk Stock Declines Ahead of Earnings Release
- Stock Performance: Novo Nordisk (NVO) fell by 1.51% to $48.89 in the latest trading session, underperforming against the S&P 500's daily loss of 0.28%, indicating market concerns regarding its short-term outlook.
- Monthly Gains: Despite the recent decline, NVO has risen by 17.66% over the past month, significantly outperforming the Medical sector's 7.8% gain and the S&P 500's 1.64% increase, suggesting sustained investor interest in its long-term growth potential.
- Earnings Expectations: The upcoming earnings report is projected to show an EPS of $0.82, reflecting a 15.46% decline year-over-year, with net sales expected at $11.35 billion, down 2.89% from the previous year, which may impact investor confidence.
- Analyst Ratings: Currently, Novo Nordisk holds a Zacks Rank of 4 (Sell), reflecting cautious sentiment from analysts regarding its short-term performance, although its forward P/E ratio of 14.67 is below the industry average of 16, indicating potential value attractiveness.
See More
Eli Lilly's Dominance in the Weight Loss Drug Market
- Market Share Growth: Eli Lilly has captured 60% of the U.S. GLP-1 drug market and 53% internationally, further solidifying its leadership position by launching the new oral weight loss drug Foundayo, which is expected to drive future sales growth.
- Surge in Sales: In the recent quarter, Lilly's weight loss products generated over $12 billion in sales, contributing to an overall sales increase of 56%, demonstrating its strong performance and profitability in the rapidly growing weight loss drug market.
- Promising R&D Pipeline: Lilly's robust pipeline in the weight loss drug sector includes the promising candidate retatrutide, currently in phase 3 trials, which has shown significant weight loss effects and is expected to provide strong support for the company's future growth.
- Evolving Competitive Landscape: While Lilly faces competition from companies like Viking Therapeutics, the strong demand for weight loss drugs indicates ample market space for multiple successful players, allowing Lilly to likely maintain its dominant market position.
See More
Analysis of Employer Coverage for GLP-1 Drugs
- Current Coverage Status: According to a survey by the International Foundation of Employee Benefit Plans, approximately 36% of employers provide coverage for GLP-1 drugs for both diabetes and weight loss, which is unchanged from 2025 but up from 34% in 2024, indicating a conservative approach towards weight loss drug coverage.
- Significant Cost Pressure: GLP-1 drugs accounted for 11.4% of annual claims in 2026, a substantial increase from 6.9% in 2023, highlighting that high drug costs are making employers more cautious in their coverage decisions, with many plans restricting or halting coverage altogether.
- Alternative Support Measures: About 27% of employers encourage employees to obtain GLP-1s through direct-to-consumer platforms, while 21% are pushing workers to use FSA, HSA, or integrated HRA funds, reflecting employers' search for alternative ways to support employee health in a high-cost environment.
- Future Coverage Potential: Although only 9% of employers are considering coverage for obesity with GLP-1s, if future evidence shows that these drugs can reduce costs in other areas, employers may reassess their coverage strategies, potentially leading to broader adoption.
See More
Eli Lilly's Drug Access Opportunities Expand
- Drug Access Breakthrough: The FDA's approval of Foundayo (forglipron) as the first GLP-1 weight management pill that can be taken anytime removes cold-chain logistics barriers, allowing more patients to access treatment and significantly expanding market reach.
- Capacity Expansion: Eli Lilly's commitment of $27 billion to build four new manufacturing sites focusing on small-molecule production demonstrates strong management confidence in future demand, indicating a strategic positioning in the drug supply chain.
- Cost Reduction Agreements: With agreements to lower costs for Medicare beneficiaries, patients can access Zepbound and Foundayo for as little as $50 a month, combined with commercial savings cards, which is expected to drive prescription growth and enhance company revenue.
- Market Competition Risks: Despite the optimistic outlook, Eli Lilly faces competition from Novo Nordisk, with potential price wars that could compress margins, and the simultaneous construction of four new plants carries execution risks, necessitating careful risk-reward assessment by investors.
See More
Eli Lilly's Foundayo Drug Could Transform Obesity Treatment Market
- New Drug Approval: Eli Lilly's oral obesity drug Foundayo has received FDA approval as the first GLP-1 pill that can be taken anytime without food or water restrictions, which is expected to significantly expand the addressable patient base by removing barriers associated with injectable treatments.
- Manufacturing Expansion: The company has committed $27 billion to build four new U.S. manufacturing sites focused on small-molecule production, indicating strong management confidence in future demand and enhancing market supply capabilities.
- Pricing Strategy Optimization: Eli Lilly has reached agreements to lower costs for Medicare beneficiaries, allowing them to pay as little as $50 a month, combined with commercial savings cards near $25, aiming to address the primary complaint about drug pricing and increase prescription fill rates.
- Market Competition Risks: While Eli Lilly holds a competitive advantage in the obesity drug market, the risks posed by Novo Nordisk's competition and the company's premium valuation cannot be overlooked, necessitating careful assessment of potential price wars and execution risks for investors.
See More
Surging Demand for GLP-1 Drugs Benefits Medical Device Companies
- Market Demand Surge: The demand for GLP-1 drugs is rapidly increasing, with companies like Eli Lilly and Novo Nordisk leading the market, although intensifying competition may lead to declining market share and pricing power.
- Becton, Dickinson Expansion Investment: Becton, Dickinson announced a $110 million investment to expand production capacity for injectable drugs to meet the soaring demand for GLP-1 medications, which is expected to enhance its competitiveness in the medical device market.
- Abbott Laboratories Growth Potential: Despite the rise of GLP-1 drugs, demand for Abbott's continuous glucose monitoring device, FreeStyle Libre, remains strong, and the combined use with GLP-1 medications may drive higher adoption rates for CGM devices.
- Stable Dividend Returns: Both Becton, Dickinson and Abbott Laboratories are Dividend Kings, having raised dividends for 54 consecutive years, demonstrating their stable revenue and profitability, which attracts long-term investors.
See More
Novo Nordisk Stock Declines Ahead of Earnings Release
- Stock Performance: Novo Nordisk (NVO) fell by 1.51% to $48.89 in the latest trading session, underperforming against the S&P 500's daily loss of 0.28%, indicating market concerns regarding its short-term outlook.
- Monthly Gains: Despite the recent decline, NVO has risen by 17.66% over the past month, significantly outperforming the Medical sector's 7.8% gain and the S&P 500's 1.64% increase, suggesting sustained investor interest in its long-term growth potential.
- Earnings Expectations: The upcoming earnings report is projected to show an EPS of $0.82, reflecting a 15.46% decline year-over-year, with net sales expected at $11.35 billion, down 2.89% from the previous year, which may impact investor confidence.
- Analyst Ratings: Currently, Novo Nordisk holds a Zacks Rank of 4 (Sell), reflecting cautious sentiment from analysts regarding its short-term performance, although its forward P/E ratio of 14.67 is below the industry average of 16, indicating potential value attractiveness.
See More
Eli Lilly's Dominance in the Weight Loss Drug Market
- Market Share Growth: Eli Lilly has captured 60% of the U.S. GLP-1 drug market and 53% internationally, further solidifying its leadership position by launching the new oral weight loss drug Foundayo, which is expected to drive future sales growth.
- Surge in Sales: In the recent quarter, Lilly's weight loss products generated over $12 billion in sales, contributing to an overall sales increase of 56%, demonstrating its strong performance and profitability in the rapidly growing weight loss drug market.
- Promising R&D Pipeline: Lilly's robust pipeline in the weight loss drug sector includes the promising candidate retatrutide, currently in phase 3 trials, which has shown significant weight loss effects and is expected to provide strong support for the company's future growth.
- Evolving Competitive Landscape: While Lilly faces competition from companies like Viking Therapeutics, the strong demand for weight loss drugs indicates ample market space for multiple successful players, allowing Lilly to likely maintain its dominant market position.
See More
Analysis of Employer Coverage for GLP-1 Drugs
- Current Coverage Status: According to a survey by the International Foundation of Employee Benefit Plans, approximately 36% of employers provide coverage for GLP-1 drugs for both diabetes and weight loss, which is unchanged from 2025 but up from 34% in 2024, indicating a conservative approach towards weight loss drug coverage.
- Significant Cost Pressure: GLP-1 drugs accounted for 11.4% of annual claims in 2026, a substantial increase from 6.9% in 2023, highlighting that high drug costs are making employers more cautious in their coverage decisions, with many plans restricting or halting coverage altogether.
- Alternative Support Measures: About 27% of employers encourage employees to obtain GLP-1s through direct-to-consumer platforms, while 21% are pushing workers to use FSA, HSA, or integrated HRA funds, reflecting employers' search for alternative ways to support employee health in a high-cost environment.
- Future Coverage Potential: Although only 9% of employers are considering coverage for obesity with GLP-1s, if future evidence shows that these drugs can reduce costs in other areas, employers may reassess their coverage strategies, potentially leading to broader adoption.
See More
Eli Lilly's Drug Access Opportunities Expand
- Drug Access Breakthrough: The FDA's approval of Foundayo (forglipron) as the first GLP-1 weight management pill that can be taken anytime removes cold-chain logistics barriers, allowing more patients to access treatment and significantly expanding market reach.
- Capacity Expansion: Eli Lilly's commitment of $27 billion to build four new manufacturing sites focusing on small-molecule production demonstrates strong management confidence in future demand, indicating a strategic positioning in the drug supply chain.
- Cost Reduction Agreements: With agreements to lower costs for Medicare beneficiaries, patients can access Zepbound and Foundayo for as little as $50 a month, combined with commercial savings cards, which is expected to drive prescription growth and enhance company revenue.
- Market Competition Risks: Despite the optimistic outlook, Eli Lilly faces competition from Novo Nordisk, with potential price wars that could compress margins, and the simultaneous construction of four new plants carries execution risks, necessitating careful risk-reward assessment by investors.
See More
Eli Lilly's Foundayo Drug Could Transform Obesity Treatment Market
- New Drug Approval: Eli Lilly's oral obesity drug Foundayo has received FDA approval as the first GLP-1 pill that can be taken anytime without food or water restrictions, which is expected to significantly expand the addressable patient base by removing barriers associated with injectable treatments.
- Manufacturing Expansion: The company has committed $27 billion to build four new U.S. manufacturing sites focused on small-molecule production, indicating strong management confidence in future demand and enhancing market supply capabilities.
- Pricing Strategy Optimization: Eli Lilly has reached agreements to lower costs for Medicare beneficiaries, allowing them to pay as little as $50 a month, combined with commercial savings cards near $25, aiming to address the primary complaint about drug pricing and increase prescription fill rates.
- Market Competition Risks: While Eli Lilly holds a competitive advantage in the obesity drug market, the risks posed by Novo Nordisk's competition and the company's premium valuation cannot be overlooked, necessitating careful assessment of potential price wars and execution risks for investors.
See More
Surging Demand for GLP-1 Drugs Benefits Medical Device Companies
- Market Demand Surge: The demand for GLP-1 drugs is rapidly increasing, with companies like Eli Lilly and Novo Nordisk leading the market, although intensifying competition may lead to declining market share and pricing power.
- Becton, Dickinson Expansion Investment: Becton, Dickinson announced a $110 million investment to expand production capacity for injectable drugs to meet the soaring demand for GLP-1 medications, which is expected to enhance its competitiveness in the medical device market.
- Abbott Laboratories Growth Potential: Despite the rise of GLP-1 drugs, demand for Abbott's continuous glucose monitoring device, FreeStyle Libre, remains strong, and the combined use with GLP-1 medications may drive higher adoption rates for CGM devices.
- Stable Dividend Returns: Both Becton, Dickinson and Abbott Laboratories are Dividend Kings, having raised dividends for 54 consecutive years, demonstrating their stable revenue and profitability, which attracts long-term investors.
See More
